These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

865 related articles for article (PubMed ID: 11714817)

  • 81. Modulation of CD8+ T cell response to antigen by the levels of self MHC class I.
    Santori FR; Arsov I; Vukmanović S
    J Immunol; 2001 May; 166(9):5416-21. PubMed ID: 11313378
    [TBL] [Abstract][Full Text] [Related]  

  • 82. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.
    Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK
    J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Interleukin (IL) 4, in the absence of antigen stimulation, induces an anergy-like state in differentiated CD8+ TC1 cells: loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines.
    Sad S; Mosmann TR
    J Exp Med; 1995 Nov; 182(5):1505-15. PubMed ID: 7595220
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Antigen-specific activation thresholds of CD8+ T cells are independent of IFN-I-mediated partial lymphocyte activation.
    Wijesundara DK; Kumar S; Alsharifi M; Müllbacher A; Regner M
    Int Immunol; 2010 Sep; 22(9):757-67. PubMed ID: 20682547
    [TBL] [Abstract][Full Text] [Related]  

  • 86. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
    Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
    J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
    [TBL] [Abstract][Full Text] [Related]  

  • 87. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
    Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
    J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae.
    Pinchuk I; Starcher BC; Livingston B; Tvninnereim A; Wu S; Appella E; Sidney J; Sette A; Wizel B
    J Immunol; 2005 May; 174(9):5729-39. PubMed ID: 15843575
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 90. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
    J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Transient loss of MHC class I tetramer binding after CD8+ T cell activation reflects altered T cell effector function.
    Drake DR; Ream RM; Lawrence CW; Braciale TJ
    J Immunol; 2005 Aug; 175(3):1507-15. PubMed ID: 16034088
    [TBL] [Abstract][Full Text] [Related]  

  • 92. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
    Baxevanis CN; Gritzapis AD; Papamichail M
    J Immunol; 2003 Sep; 171(6):2953-9. PubMed ID: 12960319
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity.
    Watanabe S; Kagamu H; Yoshizawa H; Fujita N; Tanaka H; Tanaka J; Gejyo F
    J Immunol; 2003 Dec; 171(11):5828-36. PubMed ID: 14634092
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.
    Marzo AL; Kinnear BF; Lake RA; Frelinger JJ; Collins EJ; Robinson BW; Scott B
    J Immunol; 2000 Dec; 165(11):6047-55. PubMed ID: 11086036
    [TBL] [Abstract][Full Text] [Related]  

  • 95. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses.
    Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; Hooijberg E; Kramer D; Reurs AW; van den Eertwegh AJ; von Blomberg BM; Scheper RJ; Bontkes HJ
    J Immunol; 2008 Aug; 181(4):2446-54. PubMed ID: 18684935
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
    Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
    J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen.
    Ohlén C; Kalos M; Hong DJ; Shur AC; Greenberg PD
    J Immunol; 2001 Feb; 166(4):2863-70. PubMed ID: 11160355
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity.
    La Gruta NL; Turner SJ; Doherty PC
    J Immunol; 2004 May; 172(9):5553-60. PubMed ID: 15100298
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Dendritic cells activated by an anti-inflammatory agent induce CD4(+) T helper type 2 responses without impairing CD8(+) memory and effector cytotoxic T-lymphocyte responses.
    Wang Y; Da'Dara AA; Thomas PG; Harn DA
    Immunology; 2010 Mar; 129(3):406-17. PubMed ID: 19922421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.